https://scholars.lib.ntu.edu.tw/handle/123456789/484102
標題: | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | 作者: | Shau W.-Y. YU-YUN SHAO Yeh Y.-C. ZHONG-ZHE LIN Kuo R. CHIH-HUNG HSU CHIUN HSU ANN-LII CHENG Lai M.-S. |
公開日期: | 2012 | 卷: | 17 | 期: | 6 | 起(迄)頁: | 856-862 | 來源出版物: | Oncologist | 摘要: | Background. Diabetes mellitus (DM) is closely associated with hepatocarcinogenesis. This study explores the prognostic impact ofDMin patients who received curative therapy for localized hepatocellular carcinoma (HCC). Methods. Patients who had been diagnosed with stage I or II HCC in 2003 and 2004 and received surgical resection or local ablation therapy were identified from the population- based Taiwan National Cancer Registry. Data pertaining toDMand other comorbidities were retrieved from the Taiwan National Health Insurance database. Liver cancer-specific survival (LCS), liver disease-related survival (LDS) and overall survival (OS) rates were compared between patients with and without DM. The presence of other comorbidities and tumor status were adjusted using multivariate analysis. Results.Atotal of 931 patients who fulfilled the study criteria were analyzed; 185 (20%) of them had DM (type 1 or type 2). The LCS, LDS, and OS rates were significantly worse for patients with DM than patients without DM (all p <.001). After adjusting for age, sex, tumor stage, treatment, and the presence of other comorbidities, DM remained an independent predictor of poorer LCS (hazard ratio [HR] = 1.57; p <.001), LDS (HR = 1.70; p <.001), and OS (HR = 1.69; p <.001). The associations between DM and mortality were consistent among subgroups, irrespective of tumor size, stage, treatment modality, and liver cirrhosis. Conclusions. DM is an independent factor for poorer prognosis in patients who received curative therapy for localized HCC. ? AlphaMed Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862876817&doi=10.1634%2ftheoncologist.2012-0065&partnerID=40&md5=a5dd4ad1de0ea22604a7351f635af5a5 https://scholars.lib.ntu.edu.tw/handle/123456789/484102 |
ISSN: | 1083-7159 | DOI: | 10.1634/theoncologist.2012-0065 | SDG/關鍵字: | metformin; adult; article; cancer mortality; cancer prognosis; cancer specific survival; cancer survival; comorbidity; controlled study; diabetes mellitus; disease association; disease related survival; female; human; liver cell carcinoma; major clinical study; male; overall survival; priority journal; radiofrequency ablation; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Comorbidity; Diabetes Mellitus; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prognosis; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。